PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.82%
R&D growth while RVPH reduces spending. John Neff would investigate strategic advantage.
-14.04%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.04%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
9.04%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
104.89%
Interest expense growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
EBITDA decline while RVPH shows 5.85% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
Operating income decline while RVPH shows 7.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
114.37%
Other expenses growth while RVPH reduces costs. John Neff would investigate differences.
48.96%
Pre-tax income growth exceeding 1.5x RVPH's 5.94%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
135.99%
Tax expense growth above 1.5x RVPH's 52.58%. Michael Burry would check for concerning trends.
48.96%
Net income growth exceeding 1.5x RVPH's 5.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
53.59%
EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
51.99%
Diluted EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
10.21%
Share count reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.
6.42%
Diluted share reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.